EP0000774A1 - Antithrombotische Arzneimittelkombination und Verfahren zu ihrer Herstellung - Google Patents
Antithrombotische Arzneimittelkombination und Verfahren zu ihrer Herstellung Download PDFInfo
- Publication number
- EP0000774A1 EP0000774A1 EP7878100586A EP78100586A EP0000774A1 EP 0000774 A1 EP0000774 A1 EP 0000774A1 EP 7878100586 A EP7878100586 A EP 7878100586A EP 78100586 A EP78100586 A EP 78100586A EP 0000774 A1 EP0000774 A1 EP 0000774A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pyrazolidine
- dioxo
- pyrimidine
- diphenyl
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 4
- 238000000034 method Methods 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title claims description 5
- 230000002785 anti-thrombosis Effects 0.000 title description 4
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 claims abstract description 13
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000969 carrier Substances 0.000 claims abstract description 4
- 229940127217 antithrombotic drug Drugs 0.000 claims abstract description 3
- 239000002775 capsule Substances 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000001435 Thromboembolism Diseases 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 229960002768 dipyridamole Drugs 0.000 abstract description 7
- 229960003329 sulfinpyrazone Drugs 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000282520 Papio Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000002255 antigout agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- the invention relates to a new antithrombotic drug combination and a process for its preparation.
- 2,6-bis (diethanolamino) -4,8-dipiperidino-pyrimido [5,4-d] pyrimidine (generic name: DIPYRIDAMOL) has long been used as a coronary-expanding remedy. It was first described in British Patent 807,826.
- 1,2-diphenyl-3,5-dioxo-4- (2-phenylsulfinylethyl) pyrazolidine (generic name: SULFINPYRAZON) has been on the market as an anti-gout agent for a long time, it was first published in Helv. Chim. Acta 44, 236 (1961). A good antithrombotic effect was subsequently found for both remedies, see for example Therapy Week 26, 8464-8489 (1976).
- the substance to be tested is administered orally to the awake animals (mostly) 4 times a day over the test period of 4-5 days.
- the results obtained with this method are shown in the table below:
- the table clearly shows that normalization of the shortened platelet lifespan requires 10 mg / kg / day dipyridamole or 100 mg / kg / day sulfinpyrazone, but with a combination of 2.5 mg / kg / day of the two active substances the same effect is achieved. It is known that the results can be transmitted very well on the normalization of platelet survival time from apes to humans, such as when Marx's to achieve the same effect, the same dose of D ipyridamol per kilogram is required, as in the monkey.
- the normalization of the platelet lifetime is of great therapeutic importance, since the shortening of the platelet lifetime that occurs in humans is an indication of a tendency to thrombosis.
- the new drug combination is therefore well suited for the prevention and healing of thromboembolic diseases.
- a single dose for adults contains between 25 mg and 75 mg of the two active substances, preferably 50 mg dipyridamole and 50 mg sulfinpyrazone; the single dose is preferably administered 3 times a day, the mean daily dose is therefore 150 mg / kg of each of the two active compounds. Since both active ingredients have been on the market for many years, no information about the toxicity need be given, since the toxicity is low in both cases.
- the invention further relates to a process for the preparation of the pharmaceutical combination according to the invention, which is characterized in that 2,6-bis (diethanolamino) -4,8-dipiperidino-pyrimido [5,4-d] pyrimidine and 1,2 -Diphenyl-3.5-dioxo-4- (2-phenylsulfinylethyl) -pyrazolidine in a ratio of 10: 1 to 1:10 combined and, if appropriate, with other active substances and then carriers and / or auxiliaries customary in the manufacture of medicaments to form tablets, coated tablets , Powder for letters, capsules and the like is formulated.
- the new preparations according to the invention are preferably administered orally in the doses mentioned above.
- Tablets, dragees, capsules etc. are produced in a manner known per se, for example the tablets are produced by directly compressing a mixture of the active ingredients and auxiliaries and, if appropriate, subsequently coated with a film which is compatible with the stomach and intestines during the production of the Capsules are first made separately from the powder mixture and the core with a coating and then filled on a commercially available capsule filling machine.
- Coated tablets with 50 mg dipyridamole and 50 mg sulfinpyrazone One coated tablet contains:
- the active ingredients are mixed together with milk sugar and starch and the mixture is moistened evenly with an aqueous gelatin solution.
- the moist mass is sieved to a maximum of 2 mm, dried and mixed with the lubricant after sieving again. Tablets of 400 mg were pressed from the mixture ready for compression.
- Coated core dimensions Coating:
- the kernels are coated with a conventional sugar coating suspension to 50 mg and then with sugar syrup to 530 mg / coated tablet dragierite;
- Capsule shell hard gelatin capsule size 0
- Total filling weight powder / core approx. 405 mg.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- Die Erfindung betrifft eine neue antithrombotisch wirkende Arzneimittelkombination sowie ein Verfahren zu ihrer Herstellung. 2,6-Bis(diäthanolamino)-4,8-dipiperidino-pyrimido[5,4-d]pyrimidin (generic name: DIPYRIDAMOL) wird bereits seit langem als koronarerweiterndes Heilmittel verwendet. Es wurde erstmals im britischen Patent 807 826 beschrieben. Ebenso ist 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinyläthyl)-pyrazolidin (generic name: SULFINPYRAZON) bereits seit langem als Antigichtmittel im Handel, es wurde erstmals in der Helv. chim. Acta 44, 236 (1961) beschrieben. Bei beiden Heilmitteln wurde in der Folgezeit auch eine gute antithrombotische Wirkung gefunden, siehe beispielsweise Therapiewoche 26, 8464 - 8489 (1976).
- Bei beiden Substanzen ist jedoch zur Erzielung einer-antithrombotischen Wirkung eine relativ hohe Dosis erforderlich, wobei sich schon die Nebenwirkungen beider Verbindungen bemerkbar machen; beim Dipyridamol sind es gewisse Kreislaufwirkungen, die sich in Kopfschmerzen äußern, beim Sulfinpyrazon sind es Magenschmerzen wegen der in hohen Dosen ulcerogenen Wirkung dieser Substanz. Überraschenderweise wurde nun eine starke synergistische Wirkung der beiden Wirkstoffe festgestellt. Bei einer Kombination von Dipyridamol und Sulfinpyrazon können die erforderlichen Dosen zur Erreichung des gleichen antithrombotischen Effektes wesentlich gesenkt werden. Diese synergistische Wirkung wurde im folgenden Versuchsmodell an Pavianen festgestellt:
- Männlichen Pavianen mit einem Gewicht von 8 - 12 kg wird unter Narkose ein A-V-Shunt zwischen Arteria und Vena femoralis angelegt. Dieser Shunt ist ca. 50 cm lang und besteht aus einem besonders präparierten Silastikschlauch. Durch den Fremdkörperreiz dieser körperfremden Oberfläche kommt es zu einem erhöhten Thrombozytenverbrauch (da der Organismus bestrebt ist,diesen "Defekt* abzudecken). Dieser läßt sich leicht messen, indem man dem Versuchstier mit Chrom 51 radioaktiv markierte Thrombozyten injiziert und deren Verschwinden aus der Blutbahn durch 2 x tägl. Messen verfolgt. Bei einem normalen Thrombozytenumsatz beträgt die Lebensdauer der Thrombozyten etwa 5 Tage, bei Tieren mit einem eingesetzten Shunt verkürzt sich die mittlere Thrombozytenlebenszeit (als Ausdruck eines erhöhten Thrombozytenumsatzes) auf etwa 2 - 2,5 Tage.
- Bei der Substanzprüfung wird die zu prüfende Substanz über den Versuchszeitraum von 4 - 5 Tagen den wachen Tieren (meist) 4 mal täglich oral verabreicht.
- Die bei dieser Methode erzielten Ergebnisse sind in der nachstehenden Tabelle wiedergegeben:
- Eine Einzeldosis für Erwachsene enthält zwischen 25 mg und 75 mg der beiden Wirkstoffe, vorzugsweise 50 mg Dipyridamol und 50 mg Sulfinpyrazon; die Einzeldosis wird vorzugsweise 3 mal täglich verabreicht, die mittlere Tagesdosis beträgt somit 150 mg/kg von jedem der beiden Wirkstoffe. Da.beide Wirkstoffe schon seit vielen Jahren im Handel sind, brauchen keine Angaben über die Toxizität gemacht werden, da diese in beiden Fällen gering ist.
- Gegenstand der Erfindung ist des weiteren ein Verfahren zur Herstellung der erfindungsgemäßen Arzneimittelkombination, welches dadurch gekennzeichnet ist, daß 2,6-Bis(diäthanolamino)-4,8-dipi- peridino-pyrimido[5,4-d]pyrimidin und 1,2-Diphenyl-3.5-dioxo-4-(2-phenylsulfinyläthyl)-pyrazolidin im Verhältnis von 10 : 1 bis 1 : 10 kombiniert und gegebenenfalls mit sonstigen Wirkstoffen und dan bei der Herstellung von Arzneimitteln üblichen Träger- und/oder Hilfsstoffen zu Tabletten, Dragees, Pulver für Briefe, Kapseln und dergleichen formuliert wird. Die erfindungsgemäßen neuen Präparate verden vorzugsweise peroral in den oben angeführten Dosen verab- Die Herstellung von Tabletten, Dragees, Kapseln etc. erfolgt in an sich bekannter Weise, beispielsweise werden die Tabletten durch unmittelbares Verpressen eines Gemisches der Wirk- und Hilfsstoffe hergestellt und gegebenenfalls nachträglich mit einem im Magen-und Darm verträglichen Film überzogen, bei der Herstellung der Kapseln wird erst die Pulvermischung und der Kern mit Überzug getrennt hergestellt und dann auf einer handelsüblichen Kapselabfüllmaschine abgefüllt.
- Die folgenden Beispiele erläutern die Erfindung ohne sie zu besohränken:
-
- Die Wirkstoffe werden zusammen mit Milchzucker und Stärke gemischt und die Mischung gleichmäßig mit einer wäßrigen Gelatinelösung befeuchtet. Die feuchte Masse wird auf max.2 mm gesiebt, getrocknet und nach nochmaligem Sieben mit dem Schmiermittel vermischt. Aus der so hergestellten preßfertigen Mischung wurden Tabletten von 400 mg gepreßt.
-
- Die Kerne werden mit einer üblichen Zuckerdragiersuspension auf 500 mg und anschließend mit Zuckersirup auf 530 mg/Dragee dragierit;
- Kapselhülle: Hartgelatine-Kapsel Größe 0
-
-
-
- Gesamtfüllgewicht: Pulver/Kern ca. 405 mg.
Claims (6)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19772735830 DE2735830A1 (de) | 1977-08-09 | 1977-08-09 | Antithrombotische arzneimittelkombination und verfahren zu ihrer herstellung |
DE2735830 | 1977-08-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0000774A1 true EP0000774A1 (de) | 1979-02-21 |
EP0000774B1 EP0000774B1 (de) | 1980-05-28 |
Family
ID=6015980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP78100586A Expired EP0000774B1 (de) | 1977-08-09 | 1978-08-03 | Antithrombotische Arzneimittelkombination und Verfahren zu ihrer Herstellung |
Country Status (17)
Country | Link |
---|---|
US (1) | US4206214A (de) |
EP (1) | EP0000774B1 (de) |
JP (1) | JPS5940134B2 (de) |
AU (1) | AU517484B2 (de) |
BE (1) | BE869614A (de) |
DE (2) | DE2735830A1 (de) |
FR (1) | FR2399841A1 (de) |
GB (1) | GB2002230A (de) |
IE (1) | IE47740B1 (de) |
IL (1) | IL55301A (de) |
IT (1) | IT1107571B (de) |
LU (1) | LU80083A1 (de) |
NL (1) | NL7807539A (de) |
NZ (1) | NZ188098A (de) |
PH (1) | PH14149A (de) |
SE (1) | SE7808489L (de) |
ZA (1) | ZA784470B (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0014392A1 (de) * | 1979-02-08 | 1980-08-20 | Dr. Karl Thomae GmbH | Antithrombotische Arzneimittelkombination und Verfahren zu ihrer Herstellung |
EP0019586A1 (de) * | 1979-05-11 | 1980-11-26 | Ciba-Geigy Ag | Neue antithrombotische Kombinationspräparate |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2470599A1 (fr) * | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
US4444777A (en) * | 1981-07-30 | 1984-04-24 | Bristol-Myers Company | Pharmaceutical compositions of anagrelide and sulfinpyrazone |
AT393962B (de) * | 1987-10-22 | 1992-01-10 | Thomae Gmbh Dr K | Synergistische arzneimittelkombination mit einem gehalt an einem phosphodiesterase-hemmer und derenverwendung |
CA2382547A1 (en) * | 1999-09-21 | 2001-03-29 | Stephen R. Hanson | Methods and compositions for treating platelet-related disosders |
EP1093814A1 (de) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Verwendung von Dipyridamole oder Mopidamol zur Herstellung eines Medikaments für die Behandlung und Vorbeugung von fibrinabhängigen Mikrozirkulationstörungen |
US7064130B2 (en) * | 2001-04-20 | 2006-06-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders |
JP2006516593A (ja) * | 2003-02-07 | 2006-07-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mmp−9依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3031450A (en) * | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
US3322755A (en) * | 1964-03-10 | 1967-05-30 | Boehringer Sohn Ingelheim | Basic-substituted 1, 2, 3, 4-tetrahydropyrimido [5, 4-d]-pyrimidines |
GB1190419A (en) * | 1966-08-16 | 1970-05-06 | Yamanouchi Pharma Co Ltd | Substituted Pyrimido-Pyrimidines and a process for the preparation thereof |
-
1977
- 1977-08-09 DE DE19772735830 patent/DE2735830A1/de not_active Withdrawn
-
1978
- 1978-07-13 NL NL787807539A patent/NL7807539A/xx not_active Application Discontinuation
- 1978-07-26 IT IT50483/78A patent/IT1107571B/it active
- 1978-08-01 US US05/929,940 patent/US4206214A/en not_active Expired - Lifetime
- 1978-08-03 DE DE7878100586T patent/DE2860018D1/de not_active Expired
- 1978-08-03 EP EP78100586A patent/EP0000774B1/de not_active Expired
- 1978-08-07 LU LU80083A patent/LU80083A1/de unknown
- 1978-08-07 IL IL55301A patent/IL55301A/xx unknown
- 1978-08-08 IE IE1610/78A patent/IE47740B1/en unknown
- 1978-08-08 JP JP53096562A patent/JPS5940134B2/ja not_active Expired
- 1978-08-08 ZA ZA784470A patent/ZA784470B/xx unknown
- 1978-08-08 SE SE7808489A patent/SE7808489L/xx unknown
- 1978-08-08 BE BE78189779A patent/BE869614A/xx unknown
- 1978-08-08 AU AU38735/78A patent/AU517484B2/en not_active Expired
- 1978-08-08 NZ NZ188098A patent/NZ188098A/en unknown
- 1978-08-08 GB GB7832620A patent/GB2002230A/en not_active Withdrawn
- 1978-08-09 PH PH21475A patent/PH14149A/en unknown
- 1978-08-09 FR FR7823487A patent/FR2399841A1/fr active Granted
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS, 85, 56457b (1976) & Am. J. Pathol. 1976, 83(3), 557-68 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0014392A1 (de) * | 1979-02-08 | 1980-08-20 | Dr. Karl Thomae GmbH | Antithrombotische Arzneimittelkombination und Verfahren zu ihrer Herstellung |
EP0019586A1 (de) * | 1979-05-11 | 1980-11-26 | Ciba-Geigy Ag | Neue antithrombotische Kombinationspräparate |
Also Published As
Publication number | Publication date |
---|---|
EP0000774B1 (de) | 1980-05-28 |
LU80083A1 (de) | 1979-09-06 |
AU517484B2 (en) | 1981-08-06 |
NZ188098A (en) | 1984-07-06 |
PH14149A (en) | 1981-03-06 |
BE869614A (fr) | 1979-02-08 |
IL55301A (en) | 1983-05-15 |
US4206214A (en) | 1980-06-03 |
GB2002230A (en) | 1979-02-21 |
AU3873578A (en) | 1980-02-14 |
IE781610L (en) | 1979-02-09 |
FR2399841B1 (de) | 1980-10-31 |
FR2399841A1 (fr) | 1979-03-09 |
IT7850483A0 (it) | 1978-07-26 |
JPS5428829A (en) | 1979-03-03 |
JPS5940134B2 (ja) | 1984-09-28 |
SE7808489L (sv) | 1979-02-10 |
DE2735830A1 (de) | 1979-03-01 |
IT1107571B (it) | 1985-11-25 |
NL7807539A (nl) | 1979-02-13 |
DE2860018D1 (en) | 1980-10-16 |
ZA784470B (en) | 1980-04-30 |
IE47740B1 (en) | 1984-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2224534C3 (de) | Pharmazeutisches Präparat mit langsamer Wirkstoffabgabe | |
EP0594570B1 (de) | Colestyramin als lipidsenker enthaltende präparate | |
Mahmoud et al. | Anti-inflammatory effects of tartar emetic and niridazole: suppression of schistosome egg granuloma | |
EP0796103A1 (de) | Verwendung von weihrauch zur behandlung der alzheimer-krankheit | |
CH666188A5 (de) | Immuno-regulator in form einer pharmazeutischen zusammensetzung. | |
EP0000774B1 (de) | Antithrombotische Arzneimittelkombination und Verfahren zu ihrer Herstellung | |
DE3343934A1 (de) | M-chlor-(alpha)-tert.-butylaminopropiophenon und seine verwendung zur senkung des cholesterolspiegels | |
EP0037488A2 (de) | Pharmazeutisches Mittel zur Heilung von entzündlichen und/oder degenerativen und/oder atrophischen Schleimhauterkrankungen | |
DE2507635C2 (de) | ||
DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
DE2758942A1 (de) | Kautabletten mit einem gehalt an erythromycin | |
CH638681A5 (en) | Pharmaceutical containing Echinacea and lactic acid derivatives and process for its preparation | |
DE3034975C2 (de) | Arzneimittelkombination zur Behandlung infektiöser Atemwegerkrankungen | |
DE3141970C2 (de) | ||
WO1998058639A1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
EP0014392B1 (de) | Antithrombotische Arzneimittelkombination und Verfahren zu ihrer Herstellung | |
DE3117756A1 (de) | "theophyllin-tablette" | |
DE3115033A1 (de) | "neue arzneiform fuer orale photochemotherapie" | |
DE2456172C3 (de) | Arzneimittel bei rheumatischen Erkrankungen | |
EP0123841B1 (de) | Arzneimittel mit einer die atheroprotektiven High Density Lipoproteine steigernden Wirkung, enthaltend 2,6-Bis-diäthanolamino-4,8-dipiperidino-pyrimido (5,4-d)-pyrimidin | |
DE2532180C2 (de) | Verwendung von Etozolin bei der Bekämpfung der Hypertonie | |
DE3523544A1 (de) | Nifedipin kombinationspraeparat | |
DE2823267A1 (de) | Antihypertensive praeparate | |
EP0101963A1 (de) | Neue, oral verabreichbare galenische Formen von löslichen Dimethylxanthinderivaten | |
DE3511236A1 (de) | Praeparat mit synergistischer bronchienerweiternder wirkung und verfahren zu dessen herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE |
|
17P | Request for examination filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19800831 |
|
REF | Corresponds to: |
Ref document number: 2860018 Country of ref document: DE Date of ref document: 19801016 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: AEN Free format text: DIE PATENTE SIND AM 841112 GESTUETZT AUF DIE EINGEREICHTEN WIEDEREINSETZUNGSGESUCHE AUF GRUND VON ART. 47 PATG WIEDER IN KRAFT GESETZT WORDEN. |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19890711 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19890712 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19890713 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19890731 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19890821 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19890824 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19890831 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19890914 Year of fee payment: 12 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19900803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19900804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Effective date: 19900831 Ref country code: BE Effective date: 19900831 |
|
BERE | Be: lapsed |
Owner name: KARL THOMAE G.M.B.H. Effective date: 19900831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19910301 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19910430 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19910501 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
EUG | Se: european patent has lapsed |
Ref document number: 78100586.3 Effective date: 19910410 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |